A data monitoring committee has authorized the continuation of the INVINCIBLE-3 trial of INT230-6, composed of cisplatin and vinblastine sulfate, vs SOC as a treatment for patients with locally recurrent, inoperable, or metastatic soft tissue sarcoma.